Ref.

Study Type

Intervention

Population/Sample Size

Results/Benefits

Adverse Effects

[12]

Unblinded Multicenter Trial

Nimodipine (60mg/4h orally) and IV MgSO4 of 2g/h and 1g/h

1650 women with severe pre-eclampsia

MgSo4 is more effective and has lower mortality rate than Nimodipine in women with severe pre-eclampsia

Increases the risk of PPH and respiratory difficulty

[17]

Multicenter RCT

MgSo4 Versus Diazepam Versus Phenytoin

1680 women with eclampsia from 9 countries

MgSo4 has 52% (95% CI) and 67% (95% CI) lower risk of recurrent convulsions than diazepam and phenytoin respectively

Not Reported

[18]

Prospective Trial

4g IV MgSO4 followed by i.m. injections or IV 0.6g/h

630 women with eclampsia

Both interventions are equally effective in the prevention of convulsion recurrence and maternal deaths

Not Reported

[16]

RCT

IV magnesium sulphate (4g) versus Placebo

685 Women with Severe pre-eclampsia

IV MgSo4 is effective in reducing the incidence of severe pre-eclampsia

Not Reported

[26]

RCT

IV MgSo4 (6g), followed by 2g/h

222 Women with mild pre-eclampsia

No major impact on disease progression. Does not seem to increase rates of cesarean delivery, infectious morbidity, obstetric hemorrhage.

Not Reported

[27]

SR

MgSo4 with different dose

6 RCTs with 866 women

Strong evidence in favour of MgSo4. Lack of clarity for best dose size/route

Not Reported

[13]

SR

MgSo4 Compared With Lytic Cocktail

3 small trials involving 397 women

MgSo4 is more effective in reducing MM and serious maternal morbidity than Lytic cocktail.

Recurrence of seizures.

[14]

SR

MgSO4 and Other Anticonvulsants

15 RCTs with more than 12000 women

MgSo4 reduce the risk of eclampsia by 50% (95% CI) and is more effective than phenytoin, diazepam or nimodipine

Flushing